Trabectedin for Soft Tissue Sarcoma

Evaluating the Activity of Trabectedin and Radiotherapy in Sarcoma

Gronchi says trabectedin alone and radiotherapy alone achieved tumor shrinkage in as many as 40% to 50% of patients with myxoid liposarcoma, ...

Trabectedin Now FDA-Approved for Metastatic Soft Tissue Sarcomas

Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue ...

Interruption versus continuation of trabectedin in patients with soft ...

For this open-label, non-comparative, multicentre, phase 2 study, eligible adult patients with advanced soft-tissue sarcomas, who had previously ...

A Prolonged Response and Characteristics of Trabectedin ...

The trabectedin chemotherapy experience is known for many years now and is an active agent for treatment of many soft tissue sarcomas. This agent does not have ...

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue ...

Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting ...

Trabectedin in Soft Tissue Sarcoma - YouTube

The panelists, Brian Van Tine, MD, PhD; Robin Jones, MD, MRCP; Shreyaskumar Patel, MD; Andrew Wagner, MD, PhD; and Jonathan Trent, MD, PhD; ...

Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

I mean, I think that trabectedin has really great activity in the translocation-associated sarcomas, so myxoid/round cell liposarcoma really responds well to ...

Long-Time Progression-Free Survival with Trabectedin in ...

The presented case shows that second-line trabectedin may represent a promising option for patients with chemotherapy-resistant leiomyosarcoma to prolong ...

Yondelis | European Medicines Agency (EMA)

Yondelis is used to treat adults with two types of cancer: advanced soft-tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the ...

Trabectedin for advanced soft tissue sarcomas: optimizing use | TCRM

Trabectedin is now considered an agent that is generally well tolerated, and, as it does not have the limiting cumulative side effects of a ...

Trabectedin, a drug acting on both cancer cells and the tumour ...

Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination ...

trabectedin (Yondelis) - Scottish Medicines Consortium

Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive ...

A comprehensive review of the current evidence for trabectedin in ...

It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been ...

FDA Approves New Therapeutic for Treating Certain Soft Tissue ...

Specifically, trabectedin is approved for treating patients with liposarcoma and leiomyosarcoma that cannot be removed by surgery or that is ...

Phase I Combination Study of Trabectedin and Doxorubicin in ...

Soft-tissue sarcoma (STS) is a rare type of cancer that is difficult to treat. The established standard of care for unresectable STS is ...

In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)

The FDA recently approved the minor groove DNA intercalator trabectedin (Yondelis – Janssen) for treatment of unresectable or metastatic ...

Trabectedin Fails to Improve PFS With Doxorubicin in Soft-Tissue ...

Trabectedin, which was approved by the US Food and Drug Administration in October 2015 for the treatment of soft-tissue sarcoma after treatment ...

Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)

But it's a well-tolerated drug given as a slow infusion. And this is going to get more complicated because there's an ovarian trial coming out of trabectedin ...

Trabectedin in patients with pre-treated advanced soft tissue sarcoma

Overall clinical benefit of trabectedin treatment (PR + SD) was 53%. PFS rate at six months for the entire group was 21%, median PFS was 2.5 ...

YONDELIS®

YONDELIS® is the first FDA-approved treatment for advanced soft tissue sarcoma. Learn about efficacy, side effects, risks, safety, and more.